GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

outcomes. Ophthalmology. Nov 2010;117(11):2152-2161
e2151-2152.
3. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus
delayed initiation of antiretroviral therapy for concurrent HIV
infection and cryptococcal meningitis in sub-saharan Africa. Clin
Infect Dis. Jun 1 2010;50(11):1532-1538.
4. Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence
and severity of cytomegalovirus-associated immune recovery
uveitis in HIV-infected patients with delayed highly active
antiretroviral therapy. AIDS. Apr 29 2005;19(7):735-738
5. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of
antiretroviral therapy in human immunodeficiency virus (HIV)--
associated tuberculous meningitis. Clin Infect Dis. Jun
2011;52(11):1374-1383.
6. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral
therapy reduces AIDS progression/death in individuals with acute
opportunistic infections: a multicenter randomized strategy trial.
PLoS One. 2009;4(5):e5575.
Anexo IV
1. O’Brien WA, Grovit-Ferbas K, Namazi A, et al. Human
immunodeficiency virus-type 1 replication can be increased in
peripheral blood of seropositive patients after influenza
immunization. Blood. 1995;86:1082–9.
2. Tasker SA, O’Brien WA, Treanor JJ, et al. Effects of influenza
vaccination in HIV-infectedadults: a double-blind, placebocontrolled
trial. Vaccine. 1998;16:1039–42.
3. Summary of WHO Position Papers. Recommendations for
Routine Immunization (updated: 26 Feb 2014).Disponible en:
www.who.int/immunization/policy/Immunization_routine_tabl
e1.pdf?ua=1.
4. Centers for Disease Control and Prevention. Epidemiology and
Prevention of vaccine-preventable Diseases. The Pink Book 12th
Edition Second Printing (May 2012).Disponible en:
www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/
A/immuno-table.pdf.
5. Centro Nacional de Salud para la Infancia y la Adolescencia.
Esquema de vacunación actual y vacunas.Disponible en:
http://www.censia.salud.gob.mx/contenidos/vacunas/esquema
vacunas.html.
6. Mellado Peña MJ, et al. Documento de consenso de la Sociedad
Española de Infectología Pediátrica y el Comité Asesor de Vacunas
de la Asociación Española de Pediatría para la vacunación en
inmunodeprimidos. AN. Pediatr (Barc). 2011;75(6):413.e1-
413.e22.
7. Panel on Opportunistic Infections in HIV-Exposed and HIV-
Infected Children. Guidelines for the Prevention and Treatment
of Opportunistic Infections in HIV-Exposed and HIV-Infected
Children. Department of Health and Human Services. Disponible
en http://aidsinfo.nih.gov/contentfiles/lvguidelines/
8. oi_guidelines_pediatrics.pdf.
9. Rubin et al. 2013 IDSA Clinical Practice Guideline for
Vaccination of the Immunocompromised Host.Clin Infect Dis.
2013; xx : 1 -57.
10. Advisory Committee on Immunization Practices (ACIP)
recommended immunization schedule for persons aged 0 through
18 years--United States, 2013. MMWR Surveill Summ. 2013 Feb
1;62 Suppl 1:2-8. Disponible en:
www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
Anexo V
Hoffman C. Opportunistic Infections (OIs). In: Hoffman C,
Rockstroh JK, Kamps BS, editors. HIV Medicine 2006. 4th ed.
Paris, Cagliari, Wuppertal: Flying Publisher; 2006. p. 395-480.
Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB.
Changing incidence of AIDS-defining illnesses in the era of
antiretroviral combination therapy. AIDS. 1997; 11:1731-1738.
Gullick R, Mellors J, Havlir D, et al.: Potent and sustained
antiretroviral activity of indinavir (IDV) in combination with
zidovudine (ZDV) and lamivudine (3TC). Program and abstracts
of the 3rd Conference on Retroviruses and Opportunistic
Infections; January 1996; Washington, DC. Abstract LB-7.
Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J,
et al. Reductions in HIV-1 disease progression for
zidovudine/lamivudine relative to control treatments: a metaanalysis
of controlled trials. AIDS. 1997; 11:477–483.
Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H,
et al. AIDS-Related opportunistic illnesses occurring after
initiation of potent antiretroviral therapy: The Swiss Cohort
Study. JAMA. 1999; 282: 2220-2226.
Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI,
Katzenstein T, et al. Relations among CD4 lymphocyte count
nadir, antiretroviral therapy, and HIV-1 disease progression:
results from the EuroSIDA study. Ann Intern Med. 1999; 130:
570-577.
Centers for Disease Control and Prevention (CDC). Missed
opportunities for earlier diagnosis of HIV infection -- South
Carolina, 1997-2005. MMWR Morb Mortal Wkly Rep. 2006;
55:1269-1272.
Stokes J, Pennock J. and Archibald C.P. Factors associated with
late HIV diagnosis in Canada, 1996-2005. Program and abstracts
of the AIDS 2006 - XVI InteARNtional AIDS Conference; August
13-18, 2006; Toronto, Canada. Abstract MOPE0522.
Kiwanuka N, Laeyendecker O, Laeyendecker O, Arroyo M, Robb
M, Nalugoda F, et al. Different rates of disease progression by
subtype in Rakai, Uganda. Program and abstracts of the 14th
Conference on Retroviruses and Opportunistic Infections;
February 25-28, 2007; Los Angeles, California. Abstract 307.
Chang S, Gripshover B, Kuchia M, Sethi AK. An operationalized
simple adherence assessment predicts future viral failure among
patients attending an urban U.S. HIV care clinic. Program and
abstracts of the AIDS 2006 - XVI International AIDS Conference;
August 13-18, 2006; Toronto, Canada. Abstract TUPE0124.
Keruly J, Moore R. Immune status at presentation to care has not
improved among ART-naive persons from 1990 until 2006.
Program and abstracts of the 14th Conference on Retroviruses and
Opportunistic Infections; February 25-28, 2007; Los Angeles,
California. Abstract 975.
Kunches L, Hirschhorn L, Reinhalter N, Coakley E, Musolino J,
Ban J, Massachusetts Department of Public Health and Boston
Public Health Commission Clinical Quality Management Group.
Risk factors for presenting with advanced HIV infection: results
from Massachusetts statewide chart reviews 2002-03. Program
and abstracts of the AIDS 2006 - XVI International AIDS
Conference; August 13-18, 2006; Toronto, Canada. Abstract
WEPE0225.
Likatavičius G, Devaux I, Alix J, Downs A, Nardone A. Late HIV
diagnosis in Europe. Program and abstracts of the AIDS 2006 -
XVI International AIDS Conference; August 13-18, 2006;
Toronto, Canada. Abstract MOPE0561.
Losina E, Schackman R, Sadownik S, et al. Disparities in survival
attributable to suboptimal HIV care in the US: Influence of gender
and race/ethnicity. Program and abstracts of the 14th Conference
on Retroviruses and Opportunistic Infections; February 25-28,
2007; Los Angeles, California. Abstract 142.
Matsui-Santana O, Celis de la Rosa A, Jiménez-Perez LM, Flores-
González L. AIDS mortality trends, gender and socioeconomic
development, Mexico 1988-2003. Program and abstracts of the
AIDS 2006 - XVI International AIDS Conference; August 13-18,
2006; Toronto, Canada. Abstract MOPE0307.
Vargas-Infante Y.A., Martínez-Mendizabal A, Pérez-Flores M,
Ruíz-Orozco M, Campos-López P, Saavedra J, Chang H. High
frequency of clinical progression and virological failure among
patients on antiretroviral treatment admitted to an ambulatory
HIV clinic in Puerto Vallarta, Mexico. Program and abstracts of
the 4th IAS Conference on HIV Pathogenesis, Treatment and
Prevention; July 22-25, 2007; Sydney, Australia. Abstract
CDB301.
Bartos M. Getting clear about vulnerability: focusing on the real
epidemic in Latin America. Program and abstracts of the AIDS
2006 - XVI International AIDS Conference; August 13-18, 2006;
Toronto, Canada. Abstract MOPE0874
Molton J, Smith C, Chaytor S, Maple P, Brown K, Johnson M et
al. Seroprevalence of common vaccine-preventable viral infections
in HIV-positive adults. J Infect.2010 Apr 18. (Epub ahead of
print)
Hart M, Steel A, Clark SA, Moyle G, Nelson M, Henderson DC et
al. Loss of discrete memory B cell subsets is associated with
impaired immunization responses in HIV-1 infection and may be
a risk factor for invasive pneumococcal disease. J Immunol.
2007;178:8212-20.
Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM,
Villasís-Keever A, Cuéllar-Rodríguez J, Mosqueda-Gómez JL et
al. Early loss of mézales antibodies alter MMR vaccine among
HIV-infected adults receiving HAART. Vaccine. 2009 Nov
23;27(50):7059-64.
Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L
et al. Immunogenicity of two influenza virus subunit bacines, with
or without MF59 adjuvant, administered to human
immunodeficiency virys type 1-seropositive and –seronegative
adults. Clin Vaccine Immunol. 2008 Feb;15(No. 2):253-9.
181